original articlesphase I and pharmacokineticsSafety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
phase I and pharmacokinetics
Under an Elsevier user license
open archive
Keywords
AZD5438
cyclin-dependent kinase inhibitor
hair follicle analysis
pharmacodynamics
Cited by (0)
Copyright © 2009 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.